Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery

Journal of Cardiology

Volumn 66, Issue 4, 2015, Pages 271-278

  Ivanova, Ekaterina A ^a   Parolari, Alessandro ^b   Myasoedova, Veronika ^c   Melnichenko, Alexandra A ^d,e   Bobryshev, Yuri V ^e,f,g   Orekhov, Alexander N ^d,e,h  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

^d INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^e Institute for Atherosclerosis Research   (Russian Federation)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF WESTERN SYDNEY   (Australia)

^h MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Cardiovascular disorders; Cardiovascular surgery; Cardiovascular surgical interventions; Peroxisome proliferation activated receptor gamma

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANGIOGENESIS; AORTA ANEURYSM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CORONARY STENT; DIABETES MELLITUS; GRAFT SURVIVAL; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; RESTENOSIS; REVIEW; AGONISTS; CARDIOVASCULAR DISEASES; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SURGICAL PROCEDURES; DIABETES MELLITUS; HUMANS; HYPERTENSION; PPAR GAMMA; RISK FACTORS;

EID: 84939567947     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.05.004     Document Type: Review

References (121)

1. Smirnov A.N. Nuclear receptors: nomenclature, ligands, mechanisms of their effects on gene expression. Biochemistry 2002, 67:957-977.
2. Kliewer S.A., Xu H.E., Lambert M.H., Willson T.M. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001, 56:239-263.
3. Rogue A., Spire C., Brun M., Claude N., Guillouzo A. Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res 2010, 2010:325183.
4. Chen L., Yang G. PPARs integrate the mammalian clock and energy metabolism. PPAR Res 2014, 2014:653017.
5. Boitier E., Gautier J.C., Roberts R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol 2003, 2:3.
6. Beck F., Plummer S., Senior P.V., Byrne S., Green S., Brammar W.J. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc Biol Sci 1992, 247:83-87.
7. Schäfer H.L., Linz W., Falk E., Glien M., Glombik H., Korn M., Wendler W., Herling A.W., Rütten H.A.V. E8134, a novel potent PPARalpha agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats. Acta Pharmacol 2012, 33:82-90.
8. Shah A., Rader D.J., Millar J.S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010, 210:35-40.
9. Bojic L.A., Sawyez C.G., Telford D.E., Edwards J.Y., Hegele R.A., Huff M.W. Activation of peroxisome proliferator-activated receptor delta inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein. Arterioscler Thromb Vasc Biol 2012, 32:2919-2928.
10. Millar J.S. Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk. Curr Opin Lipidol 2013, 24:233-238.
11. Janani C., Ranjitha Kumari B.D. PPAR gamma gene - a review. Diabetes Metab Syndr 2015, 9:46-50.
12. Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45:120-159.
13. Kintscher U., Law R.E. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 2005, 288:E287-E291.
14. Wilding J.P. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab 2012, 14:973-982.
15. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., Viberti G., ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
16. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
17. Cipolletta D., Feuerer M., Li A., Kamei N., Lee J., Shoelson S.E., Benoist C., Mathis D. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486:549-553.
18. Matsubara T., Mita A., Minami K., Hosooka T., Kitazawa S., Takahashi K., Tamori Y., Yokoi N., Watanabe M., Matsuo E., Nishimura O., Seino S. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 2012, 15:38-50.
19. Yoshimoto T., Naruse M., Nishikawa M., Naruse K., Tanabe A., Seki T., Imaki T., Demura R., Aikawa E., Demura H. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997, 272:E989-E996.
20. Walker A.B., Naderali E.K., Chattington P.D., Buckingham R.E., Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998, 47:810-814.
21. Krishnaswami A., Ravi-Kumar S., Lewis J.M. Thiazolidinediones: a 2010 perspective. Perm J 2010, 14:64-72.
22. Rennings A.J., Russel F.G., Li Y., Deen P.M., Maseseeuw R., Tack C.J., Smits P. Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study. Clin Pharmacol Ther 2011, 89:587-594.
23. Chang C., Tsai P., Sung J., Chen J., Ho L., Pandya K., Maeda N., Tsai Y. Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. Am J Pathol 2014, 184:442-453.
24. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferators-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005, 97:372-379.
25. Festuccia W.T., Laplante M., Brule S., Houde V.P., Achouba A., Lachance D., Pedrosa M.L., Silva M.E., Guerra-Sa R., Couet J., Arsenault M., Marette A., Deshaies Y. Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. J Mol Cell Cardiol 2009, 47:85-95.
26. Mannucci E., Monami M., Di Bari M., Lamanna C., Gori F., Gensini G.F., Marchionni N. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2010, 143:135-140.
27. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., Saito T., Masuda Y., Kadowaki T., Komuro I. Peroxisome proliferators-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002, 105:1240-1246.
28. Abou Daya K., Abu Daya H., Nasser Eddine M., Nahhas G., Nuwayri-Salti N. Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats. J Diabetes 2015, 7:85-94.
29. Balas B., Belfort R., Harrison S.A., Darland C., Finch J., Schenker S., Gastaldelli A., Cusi K. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007, 47:565-570.
30. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefèbvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
31. Dormandy J., Bhattacharya M., van Troostenburg de Bruyn A.R., PROactive investigators Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009, 32:187-202.
32. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
33. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. Br Med J 2011, 342:d1309.
34. Diamant M., Heine R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003, 63:1373-1405.
35. Peters Harmel A.L., Kendall D.M., Buse J.B., Boyle P.J., Marchetti A., Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004, 20:215-223.
36. Nagashima K., Lopez C., Donovan D., Ngai C., Fontanez N., Bensadoun A., Fruchart-Najib J., Holleran S., Cohn J.S., Ramakrishnan R., Ginsberg H.N. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005, 115:1323-1332.
37. Staels B. PPARgamma and atherosclerosis. Curr Med Res Opin 2005, 21(Suppl. 1):S13-S20.
38. Orekhov A.N., Sobenin I.A., Gavrilin M.A., Gratchev A., Kotyashova S.Y., Nikiforov N.G., Kzhyshkowska J. Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy. Curr Pharm Des 2015, 21:1172-1179.
39. Peled M., Fisher E.A. Dynamic aspects of macrophage polarization during atherosclerosis progression and regression. Front Immunol 2014, 5:579.
40. Duan S.Z., Usher M.G., Mortensen R.M. PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 2009, 18:128-133.
41. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
42. Berry A., Balard P., Coste A., Olagnier D., Lagane C., Authier H., Benoit-Vical F., Lepert J.C., Séguéla J.P., Magnaval J.F., Chambon P., Metzger D., Desvergne B., Wahli W., Auwerx J., et al. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur J Immunol 2007, 37:1642-1652.
43. Bobryshev Y.V., Lord R.S. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res 1998, 37:799-810.
44. Bobryshev Y.V. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005, 26:1700-1704.
45. Nencioni A., Grünebach F., Zobywlaski A., Denzlinger C., Brugger W., Brossart P. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol 2002, 169:1228-1235.
46. Széles L., Töröcsik D., Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 2007, 1771:1014-1030.
47. Szatmari I., Töröcsik D., Agostini M., Nagy T., Gurnell M., Barta E., Chatterjee K., Nagy L. PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007, 110:3271-3280.
48. Su W., Sun A., Xu D., Zhang H., Yang L., Yuan L., Jia J., Zou Y., Wu Y., Wang K., Ge J. Tongxinluo inhibits oxidized low-density lipoprotein-induced maturation of human dendritic cells via activating peroxisome proliferator-activated receptor gamma pathway. J Cardiovasc Pharmacol 2010, 56:177-183.
49. Liu H., Wang S., Sun A., Huang D., Wang W., Zhang C., Shi D., Chen K., Zou Y., Ge J. Danhong inhibits oxidized low-density lipoprotein-induced immune maturation of dendritic cells via a peroxisome proliferator activated receptor γ-mediated pathway. J Pharmacol Sci 2012, 119:1-9.
50. Ohshima K., Mogi M., Horiuchi M. Role of peroxisome proliferator-activated receptor -γ in vascular inflammation. Int J Vasc Med 2012, 2012:508416.
51. Perrin-Cocon L., Diaz O., André P., Lotteau V. Modified lipoproteins provide lipids that modulate dendritic cell immune function. Biochimie 2013, 95:103-108.
52. Sugawara A., Uruno A., Matsuda K., Saito-Ito T., Funato T., Saito-Hakoda A., Kudo M., Ito S. Effects of PPARgamma agonists against vascular and renal dysfunction. Curr Mol Pharmacol 2012, 5:248-254.
53. Ikeda Y., Sugawara A., Taniyama Y., Uruno A., Igarashi K., Arima S., Ito S., Takeuchi K. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2. J Biol Chem 2000, 275:33142-33150.
54. Sugawara A., Uruno A., Kudo M., Ikeda Y., Sato K., Taniyama Y., Ito S., Takeuchi K. Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J Biol Chem 2002, 277:9676-9683.
55. Majithiya J.B., Paramar A.N., Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 2005, 66:150-161.
56. Miike T., Kunishiro K., Kanda M., Azukizawa S., Kurahashi K., Shirahase H. Impairment of endothelium-dependent ACh-induced relaxation in aorta of diabetic db/db mice--possible dysfunction of receptor and/or receptor-G protein coupling. Naunyn-Schmiedeberg's Arch Pharmacol 2008, 377:401-410.
57. Martens F.M., Visseren F.L., de Koning E.J., Rabelink T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005, 46:773-778.
58. Staniloae C., Mandadi V., Kurian D., Coppola J., Bernaski E., El-Khally Z., Morlote M., Pinassi E., Ambrose J. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 2007, 108:164-169.
59. Sarafidis P.A., Lasaridis A.N. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006, 19:64653.
60. Sugawara A., Takeuchi K., Uruno A., Ikeda Y., Arima S., Kudo M., Sato K., Taniyama Y., Ito S. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001, 142:3125-3134.
61. Uruno A., Matsuda K., Noguchi N., Yoshikawa T., Kudo M., Satoh F., Rainey W.E., Hui X.G., Akahira J., Nakamura Y., Sasano H., Okamoto H., Ito S., Sugawara A. Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J Mol Endocrinol 2011, 46:37-49.
62. Benkirane K., Viel E.C., Amiri F., Schiffrin E.L. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 2006, 47:102-108.
63. Tsai Y.S., Xu L., Smithies O., Maeda N. Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure. Proc Natl Acad Sci U S A 2009, 106:19084-19089.
64. Tammela T., Enholm B., Alitalo K., Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005, 65:550-563.
65. Biscetti F., Gaetani E., Flex A., Aprahamian T., Hopkins T., Straface G., Pecorini G., Stigliano E., Smith R.C., Angelini F., Castellot J.J., Pola R. Selective activation of peroxisome proliferators-activated receptor (PPAR) alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008, 57:1394-1404.
66. Murata T., He S., Hangai M., Ishibashi T., Xi X.P., Kim S., Hsueh W.A., Ryan S.J., Law R.E., Hinton D.R. Peroxisome proliferators-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000, 41:2309-2317.
67. Fukunaga Y., Itoh H., Doi K., Tanaka T., Yamashita J., Chun T.H., Inoue M., Masatsugu K., Sawada N., Saito T., Hosoda K., Kook H., Ueda M., Nakao K. Thiazolidinediones, peroxisome proliferators-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001, 158:113-119.
68. Fujii M., Inoki I., Saga M., Morikawa N., Arakawa K., Inaba S., Yoshioka K., Konoshita T., Miyamori I. Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferators-activated receptor gamma. J Steroid Biochem Mol Biol 2012, 129:145-152.
69. Wolf D., Tseng N., Seedorf G., Roe G., Abman S.H., Gien J. Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2014, 306:L361-L371.
70. Zhang F., Kong D., Chen L., Zhang X., Lian N., Zhu X., Lu Y., Zheng S. Peroxisome proliferators-activated receptor-γ interrupts angiogenic signal transduction by transrepression of platelet-derived growth factor-β receptor in hepatic stellate cells. J Cell Science 2014, 127:305-314.
71. Yang J., Zhang D., Li J., Zhang X., Fan F., Guan Y. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clin Sci 2009, 116:17-26.
72. Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010, 55:835-847.
73. Chung B.H., Lim S.W., Ahn K.O., Sugawara A., Ito S., Choi B.S., Kim Y.S., Bang B.K., Yang C.W. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology 2005, 10(Suppl.):S40-S43.
74. Iglesias P., Diez J.J. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006, 154:613-621.
75. Chung B.H., Li C., Sun B.K., Lim S.W., Ahn K.O., Yang J.H., Choi Y.H., Yoon K.H., Sugawara A., Ito S., Kim J., Yang C.W. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005, 5:1856-1867.
76. Yoshihara D., Kurahashi H., Morita M., Kugita M., Hiki Y., Aukema H.M., Yamaguchi T., Calvet J.P., Wallace D.P., Nagao S. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011, 300:F465-F474.
77. Zuo Y., Yang H.C., Potthoff S.A., Najafian B., Kon V., Ma L.J., Fogo A.B. Protective effects of PPARgamma agonist in acute nephrotic syndrome. Nephrol Dial Transplant 2012, 27:174-181.
78. Prisant L.M., Mondy J.S. Abdominal aortic aneurysm. J Clin Hypertens 2004, 6:85-89.
79. Santilli J.D., Santilli S.M. Diagnosis and treatment of abdominal aortic aneurysms. Am Fam Physician 1997, 56:1081-1090.
80. Sorice G.P., Folli F. A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes). Med Hypotheses 2009, 73:614-618.
81. Barbour J.R., Spinale F.G., Ikonomidis J.S. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res 2007, 139:292-307.
82. Wilson W.R., Anderton M., Schwalbe E.C., Jones J.L., Furness P.N., Bell P.R., Thompson M.M. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 2006, 113:438-445.
83. Bunton T.E., Biery N.J., Myers L., Gayraud B., Ramirez F., Dietz H.C. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001, 88:37-43.
84. Neptune E.R., Frischmeyer P.A., Arking D.E., Myers L., Bunton T.E., Gayraud B., Ramirez F., Sakai L.Y., Dietz H.C. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33:407-411.
85. Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H., Pannu H., De Backer J.F., Oswald G.L., Symoens S., Manouvrier S., Roberts A.E., Faravelli F., Greco M.A., Pyeritz R.E., Milewicz D.M., et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006, 355:788-798.
86. Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A., Spevak P.J., Cameron D.E., De Backer J., et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275-281.
87. Ghosh A.K., Bhattacharyya S., Lakos G., Chen S.J., Mori Y., Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004, 50:1305-1318.
88. Joner M., Farb A., Cheng Q., Finn A.V., Acampado E., Burke A.P., Skorija K., Creighton W., Kolodgie F.D., Gold H.K., Virmani R. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 2007, 27:182-189.
89. Imanishi T., Kobayashi K., Kuroi A., Ikejima H., Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens Res 2008, 31:757-765.
90. Chen J., Mehta J.L. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 2006, 291:H1738-H1745.
91. Moran C.S., Cullen B., Campbell J.H., Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J Vasc Res 2009, 46:209-217.
92. Moran C.S., Clancy P., Biros E., Blanco-Martin B., McCaskie P., Palmer L.J., Coomans D., Norman P.E., Golledge J. Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm. Clin Endocrinol 2010, 72:128-132.
93. Weintraub W.S., Stein B., Kosinski A., Douglas J.S., Ghazzal Z.M., Jones E.L., Morris D.C., Guyton R.A., Craver J.M., King S.B. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998, 31:10-19.
94. Fonseca V.A., Diez J., McNamara D.B. Decreasing restenosis following angioplasty: the potential of peroxisome proliferator-activated receptor gamma agonists. Diabetes Care 2004, 27:2764-2766.
95. Piatti P., Di Mario C., Monti L.D., Fragasso G., Sgura F., Caumo A., Setola E., Lucotti P., Galluccio E., Ronchi C., Origgi A., Zavaroni I., Margonato A., Colombo A. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003, 108:2074-2081.
96. Lim S., Jin C.J., Kim M., Chung S.S., Park H.S., Lee I.K., Lee C.T., Cho Y.M., Lee H.K., Park K.S. PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 2006, 26:808-813.
97. Marx N., Wöhrle J., Nusser T., Walcher D., Rinker A., Hombach V., Koenig W., Höher M. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112:2792-2798.
98. Nishio K., Sakurai M., Kusuyama T., Shigemitsu M., Fukui T., Kawamura K., Itoh S., Konno N., Katagiri T. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006, 29:101-106.
99. Rosmarakis E.S., Falagas M.E. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 2007, 154:144-150.
100. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., Hsueh W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
101. Aizawa Y., Kawabe J., Hasebe N., Takehara N., Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001, 104:455-460.
102. Rajamannan N.M., Subramaniam M., Rickard D., Stock S.R., Donovan J., Springett M., Orszulak T., Fullerton D.A., Tajik A.J., Bonow R.O., Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003, 107:2181-2184.
103. Boström K., Watson K.E., Horn S., Wortham C., Herman I.M., Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993, 91:1800-1809.
104. Kawaguchi H., Akune T., Yamaguchi M., Ohba S., Ogata N., Chung U.I., Kubota N., Terauchi Y., Kadowaki T., Nakamura K. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab 2005, 23:275-279.
105. Mody N., Parhami F., Sarafian T.A., Demer L.L. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001, 31:509-519.
106. Miller J.D., Chu Y., Brooks R.M., Richenbacher W.E., Peña-Silva R., Heistad D.D. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008, 52:843-850.
107. Chu Y., Lund D.D., Weiss R.M., Brooks R.M., Doshi H., Hajj G.P., Sigmund C.D., Heistad D.D. Pioglitazone attenuates valvular calcification induced by hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013, 33:523-532.
108. Jaswal J.S., Keung W., Wang W., Ussher J.R., Lopaschuk G.D. Targeting fatty acid and carbohydrate oxidation-a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 2011, 1813:1333-1350.
109. Cao Z., Ye P., Long C., Chen K., Li X., Wang H. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pharmacology 2007, 79:184-192.
110. Hobson M.J., Hake P.W., O'Connor M., Schulte C., Moore V., James J.M., Piraino G., Zingarelli B. Conditional deletion of cardiomyocyte peroxisome proliferator-activated receptor gamma enhances myocardial ischemia-reperfusion injury in mice. Shock 2014, 41:40-47.
111. Hu Q., Chen J., Jiang C., Liu H.F. Effect of peroxisome proliferator-activated receptor gamma agonist on heart of rabbits with acute myocardial ischemia/reperfusion injury. Asian Pac J Trop Med 2014, 7:271-275.
112. Cross T.G., Scheel-Toellner D., Henriquez N.V., Deacon E., Salmon M., Lord J.M. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000, 256:34-41.
113. Adderley S.R., Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999, 274:5038-5046.
114. Wang H., Zhu Q.W., Ye P., Li Z.B., Li Y., Cao Z.L., Shen L. Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2. Biosci Trends 2012, 6:325-332.
115. Liu B., Liang G., Xu G., Liu D., Cai Q., Gao Z. Intervention of rosiglitazone on myocardium Glut-4 mRNA expression during ischemia-reperfusion injury in cardio-pulmonary bypass in dogs. Mol Cell Biochem 2013, 373:279-284.
116. Zhang Q.W., Kish D.D., Fairchild R.L. Absence of allograft ICAM-1 attenuates alloantigen-specific T cell priming, but not primed T cell trafficking into the graft, to mediate acute rejection. J Immunol 2003, 170:5530-5537.
117. Ramzy D., Rao V., Brahm J., Miriuka S., Delgado D., Ross H.J. Cardiac allograft vasculopathy: a review. Can J Surg 2005, 48:319-327.
118. Kosuge H., Haraguchi G., Koga N., Maejima Y., Suzuki J., Isobe M. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 2006, 113:2613-2622.
119. Ye P., Li J., Wang S., Xie A., Sun W., Xia J. Eicosapentaenoic acid disrupts the balance between Tregs and IL-17+ T cells through PPARgamma nuclear receptor activation and protects cardiac allografts. J Surg Res 2012, 173:161-170.
120. Yin R., Huang H., Zhang J., Zhu J., Jing H., Li Z. Dietary n-3 fatty acids attenuate cardiac allograft vasculopathy via activating peroxisome proliferator-activated receptor-gamma. Pediatr Transplant 2008, 12:550-556.
121. Chen Y., Li D., Tsang J.Y., Niu N., Peng J., Zhu J., Hui K., Xu A., Lui V.C., Lamb J.R., Tam P.K. PPAR-gamma signaling and IL-5 inhibition together prevent chronic rejection of MHC Class II-mismatched cardiac grafts. J Heart Lung Transplant 2011, 30:698-706.